LOXL4 and central nervous system cancer: The results shown in CGGA-325 dataset revealed that the glioma patients with the high levels of all members of LOX family including LOX, LOXL1, LOXL2, LOXL3, and LOXL4 displayed poor prognosis with the MST of only 34.3, 31, 31, 35.3, and 34.8 months, respectively (Figures 4A,D,G,J,M).